Hematopoietic stem cell transplantation for cardiac and peripheral vascular disease

R. Burt*, W. Pearce, K. Luo, Y. Oyama, C. Davidson, N. Beohar, M. Gheorghiade

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Recent studies have suggested that marrow and blood hematopoietic stem cells may contribute to nonhematopoietic tissue repair in multiple organ systems. In animal models and more recently in limited human trials, unpurified marrow mononuclear cells and/or subsets of adult hematopoietic stem cells have been reported to contribute to neoangiogenesis. Since the subset of hematopoietic stem cells (HSCs) that are both CD34+ and AC133+ are endothelial cell precursors, clinical trials using autologous AC133+ HSCs isolated with the Miltenyi CLIMACS cell separator and transplanted into patients with ischemic and refractory peripheral vascular or coronary artery disease are being implemented at Northwestern University.

Original languageEnglish (US)
Pages (from-to)S29-S31
JournalBone Marrow Transplantation
StatePublished - Aug 2003


  • Coronary artery disease
  • Hematopoietic stem cell
  • Peripheral vascular disease

ASJC Scopus subject areas

  • Transplantation
  • Hematology


Dive into the research topics of 'Hematopoietic stem cell transplantation for cardiac and peripheral vascular disease'. Together they form a unique fingerprint.

Cite this